{"id":109264,"date":"2025-08-31T19:39:14","date_gmt":"2025-08-31T19:39:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/109264\/"},"modified":"2025-08-31T19:39:14","modified_gmt":"2025-08-31T19:39:14","slug":"coronary-flow-reserve-increase-after-4-year-dapagliflozin-treatment-in-patients-with-type-2-diabetes-the-dapaheart-follow-up-study-cardiovascular-diabetology","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/109264\/","title":{"rendered":"Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study | Cardiovascular Diabetology"},"content":{"rendered":"<p>Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with a significantly increased risk of cardiovascular (CV) disease, including coronary artery disease (CAD) and heart failure (HF) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 1\" title=\"De Rosa S, et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2. &#010;                  https:\/\/doi.org\/10.3389\/fendo.2018.00002&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR1\" id=\"ref-link-section-d469242517e1011\" rel=\"nofollow noopener\" target=\"_blank\">1<\/a>]. Despite advancements in glycemic control therapies, reducing CV morbidity and mortality in T2DM patients remains a critical challenge [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 2\" title=\"Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008\u201317. &#010;                  https:\/\/doi.org\/10.1016\/S0140-6736(14)60794-7&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR2\" id=\"ref-link-section-d469242517e1014\" rel=\"nofollow noopener\" target=\"_blank\">2<\/a>]. Although microvascular complications are closely associated with CV morbidity, and glycemic control effectively reduces microvascular damage, to date, no trial has conclusively demonstrated that lowering HbA1c alone significantly reduces major adverse cardiovascular events (MACE) in patients with established microvascular or macrovascular disease, i.e., in the context of secondary prevention [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 3\" title=\"Mahaffey KW, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018;137:323\u201334. &#010;                  https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR3\" id=\"ref-link-section-d469242517e1017\" rel=\"nofollow noopener\" target=\"_blank\">3<\/a>]. However, some therapies have shown cardioprotective effects, reducing MACE independently of glycemic control [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (sglt2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344. &#010;                  https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR4\" id=\"ref-link-section-d469242517e1020\" rel=\"nofollow noopener\" target=\"_blank\">4<\/a>]. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) represent a breakthrough in the management of T2DM, with extensive cardiovascular outcome trials (CVOTs) showing reductions in CV mortality, HF hospitalizations, and renal disease progression [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Cinti F, et al. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: fact or fiction? Cardiovasc Diabetol. 2025;24:208. &#10;                  https:\/\/doi.org\/10.1186\/s12933-025-02767-9&#10;                  &#10;                .\" href=\"#ref-CR5\" id=\"ref-link-section-d469242517e1023\">5<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"D\u2019Amario D, et al. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2024;11:2063\u201375. &#10;                  https:\/\/doi.org\/10.1002\/ehf2.14626&#10;                  &#10;                .\" href=\"#ref-CR6\" id=\"ref-link-section-d469242517e1023_1\">6<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139. &#10;                  https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X&#10;                  &#10;                .\" href=\"#ref-CR7\" id=\"ref-link-section-d469242517e1023_2\">7<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Scheen AJ. EMPA-REG OUTCOME: empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk. Rev Med Liege. 2015;70:583\u20139.\" href=\"#ref-CR8\" id=\"ref-link-section-d469242517e1023_3\">8<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 9\" title=\"Beernink JM, et al. Efficacy of Dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care. 2023;46:602\u20137. &#010;                  https:\/\/doi.org\/10.2337\/dc22-1514&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR9\" id=\"ref-link-section-d469242517e1027\" rel=\"nofollow noopener\" target=\"_blank\">9<\/a>].<\/p>\n<p>Coronary flow reserve (CFR), a key marker of cardiovascular health, particularly in patients with type 2 diabetes mellitus (T2DM) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 10\" title=\"Niewiara L, et al. Impaired coronary flow reserve in patients with poor type 2 diabetes control: preliminary results from prospective microvascular dysfunction registry. Cardiol J. 2024;31:185\u201392. &#010;                  https:\/\/doi.org\/10.5603\/CJ.a2022.0100&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR10\" id=\"ref-link-section-d469242517e1033\" rel=\"nofollow noopener\" target=\"_blank\">10<\/a>], is a fundamental indicator of coronary circulation, reflecting the ability of coronary arteries to increase blood flow during stress compared to rest (CFR\u2009=\u2009myocardial blood flow [MBF] at stress\/MBF at rest) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 11\" title=\"Galante D, et al. Fractional flow reserve (FFR) and index of microcirculatory resistance (IMR) relationship in patients with chronic or stabilized acute coronary syndromes. Int J Cardiol. 2025;422:132978. &#010;                  https:\/\/doi.org\/10.1016\/j.ijcard.2025.132978&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR11\" id=\"ref-link-section-d469242517e1036\" rel=\"nofollow noopener\" target=\"_blank\">11<\/a>]. In T2DM, CFR is frequently reduced due to microvascular dysfunction, [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 12\" title=\"Nitenberg A, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993;42:1017\u201325. &#010;                  https:\/\/doi.org\/10.2337\/diab.42.7.1017&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR12\" id=\"ref-link-section-d469242517e1039\" rel=\"nofollow noopener\" target=\"_blank\">12<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 13\" title=\"Nitenberg A, et al. Impairment of coronary microvascular dilation in response to cold pressor\u2013induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes. 2001;50:1180\u20135. &#010;                  https:\/\/doi.org\/10.2337\/diabetes.50.5.1180&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR13\" id=\"ref-link-section-d469242517e1042\" rel=\"nofollow noopener\" target=\"_blank\">13<\/a>] which contributes to a higher risk of ischemic events [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"D\u2019Amario D, et al. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2024;11:2063\u201375. &#010;                  https:\/\/doi.org\/10.1002\/ehf2.14626&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR6\" id=\"ref-link-section-d469242517e1045\" rel=\"nofollow noopener\" target=\"_blank\">6<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 14\" title=\"Kato S, et al. Coronary flow reserve by cardiac magnetic resonance imaging in patients with diabetes mellitus. JACC Cardiovasc Imaging. 2019;12:2579\u201380. &#010;                  https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.010&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR14\" id=\"ref-link-section-d469242517e1049\" rel=\"nofollow noopener\" target=\"_blank\">14<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 15\" title=\"Nesti L, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21:181. &#010;                  https:\/\/doi.org\/10.1186\/s12933-022-01618-1&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR15\" id=\"ref-link-section-d469242517e1052\" rel=\"nofollow noopener\" target=\"_blank\">15<\/a>]. A potential cause of microvascular dysfunction may be the loss of the cardio protective effect of epicardial adipose tissue (EAT) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 16\" title=\"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593\u2013606. &#010;                  https:\/\/doi.org\/10.1038\/s41569-022-00679-9&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR16\" id=\"ref-link-section-d469242517e1055\" rel=\"nofollow noopener\" target=\"_blank\">16<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 17\" title=\"Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101\u201311. &#010;                  https:\/\/doi.org\/10.1093\/eurheartj\/eht513&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR17\" id=\"ref-link-section-d469242517e1058\" rel=\"nofollow noopener\" target=\"_blank\">17<\/a>]. In type 2 diabetes, this distinct brown adipose tissue depot has been reported to undergo morphological and functional alterations shifting toward white adipose tissue characteristics along with increased thickening and inflammation16. Increased inflammation of EAT, indicated by the whitening of brown adipose tissue, has been widely documented in the literature [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Malavazos AE, et al. The density of crown-like structures in epicardial adipose tissue could play a role in cardiovascular diseases. Eat Weight Disord. 2022;27:2905\u201310. &#10;                  https:\/\/doi.org\/10.1007\/s40519-022-01420-8&#10;                  &#10;                .\" href=\"#ref-CR18\" id=\"ref-link-section-d469242517e1063\">18<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Giordano A, et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res. 2013;54:2423\u201336. &#10;                  https:\/\/doi.org\/10.1194\/jlr.M038638&#10;                  &#10;                .\" href=\"#ref-CR19\" id=\"ref-link-section-d469242517e1063_1\">19<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Kotzbeck P, et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res. 2018;59:784\u201394. &#10;                  https:\/\/doi.org\/10.1194\/jlr.M079665&#10;                  &#10;                .\" href=\"#ref-CR20\" id=\"ref-link-section-d469242517e1063_2\">20<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 21\" title=\"Giordano A, et al. The adipose organ is a unitary structure in mice and humans. Biomedicines. 2022;10(9):2275. &#010;                  https:\/\/doi.org\/10.3390\/biomedicines10092275&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR21\" id=\"ref-link-section-d469242517e1067\" rel=\"nofollow noopener\" target=\"_blank\">21<\/a>]. Chronic inflammation contributes to microvascular dysfunction, which is detectable through a reduction in CFR [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"Recio-Mayoral A, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009;30:1837\u201343. &#010;                  https:\/\/doi.org\/10.1093\/eurheartj\/ehp205&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR22\" id=\"ref-link-section-d469242517e1070\" rel=\"nofollow noopener\" target=\"_blank\">22<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 23\" title=\"Taqueti VR, Ridker PM. Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. JACC Cardiovasc Imaging. 2013;6:668\u201371. &#010;                  https:\/\/doi.org\/10.1016\/j.jcmg.2013.02.005&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR23\" id=\"ref-link-section-d469242517e1073\" rel=\"nofollow noopener\" target=\"_blank\">23<\/a>]. Due to its close anatomical proximity to the heart and its potential to regain its anti-inflammatory molecule secreting activity, thus improving CFR, EAT is now recognized as an important, independent, and modifiable cardiovascular risk factor [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Iacobellis G, Baroni MG. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. 2022;45:489\u201395. &#10;                  https:\/\/doi.org\/10.1007\/s40618-021-01687-1&#10;                  &#10;                .\" href=\"#ref-CR24\" id=\"ref-link-section-d469242517e1076\">24<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Pedicino D, et al. Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. Int J Cardiol. 2017;236:95\u20139. &#10;                  https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.040&#10;                  &#10;                .\" href=\"#ref-CR25\" id=\"ref-link-section-d469242517e1076_1\">25<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 26\" title=\"Antoniades C, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023. &#010;                  https:\/\/doi.org\/10.1093\/eurheartj\/ehad484&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR26\" id=\"ref-link-section-d469242517e1079\" rel=\"nofollow noopener\" target=\"_blank\">26<\/a>].<\/p>\n<p>Another potential consequence of microvascular dysfunction is the reduction in myocardial mechano-energetic efficiency (MEEi) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 27\" title=\"Succurro E, et al. Impaired insulin-stimulated myocardial glucose metabolic rate is associated with reduced estimated myocardial energetic efficiency in subjects with different degrees of glucose tolerance. Cardiovasc Diabetol. 2023;22:4. &#010;                  https:\/\/doi.org\/10.1186\/s12933-022-01733-z&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR27\" id=\"ref-link-section-d469242517e1085\" rel=\"nofollow noopener\" target=\"_blank\">27<\/a>], a measure of cardiac performance, which assesses the heart&#8217;s efficiency in converting metabolic energy into mechanical work [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Vanessa Fiorentino T, et al. Depressed myocardial mechano-energetic efficiency in subjects with dysglycemia. Diabetes Res Clin Pract. 2021;177:108883. &#010;                  https:\/\/doi.org\/10.1016\/j.diabres.2021.108883&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR28\" id=\"ref-link-section-d469242517e1088\" rel=\"nofollow noopener\" target=\"_blank\">28<\/a>]. MEEi, which is typically reduced in T2DM, due to cardiac insulin resistance and altered substrate utilization [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Vanessa Fiorentino T, et al. Depressed myocardial mechano-energetic efficiency in subjects with dysglycemia. Diabetes Res Clin Pract. 2021;177:108883. &#010;                  https:\/\/doi.org\/10.1016\/j.diabres.2021.108883&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR28\" id=\"ref-link-section-d469242517e1091\" rel=\"nofollow noopener\" target=\"_blank\">28<\/a>], provides valuable insights into the functional impact of therapeutic interventions on myocardial efficiency [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 15\" title=\"Nesti L, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21:181. &#010;                  https:\/\/doi.org\/10.1186\/s12933-022-01618-1&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR15\" id=\"ref-link-section-d469242517e1094\" rel=\"nofollow noopener\" target=\"_blank\">15<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 29\" title=\"Mancusi C, et al. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network. J Hum Hypertens. 2017;31:424. &#010;                  https:\/\/doi.org\/10.1038\/jhh.2017.3&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR29\" id=\"ref-link-section-d469242517e1097\" rel=\"nofollow noopener\" target=\"_blank\">29<\/a>]. Preserving or improving MEEi is essential for maintaining cardiac energy efficiency in this high-risk population.<\/p>\n<p>In the DAPAHEART trial, a recent single-center, 4-week, randomized, double-blind, controlled study (1:1 dapagliflozin 10\u00a0mg vs. placebo), we demonstrated that treatment with dapagliflozin induced a 30% increase in CFR in patients with T2DM and stable CAD [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 30\" title=\"Sorice GP, et al. Effect of dapagliflozin on myocardial insulin sensitivity and perfusion: rationale and design of the DAPAHEART trial. Diabetes Ther. 2021;12:2101\u201313. &#010;                  https:\/\/doi.org\/10.1007\/s13300-021-01083-1&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR30\" id=\"ref-link-section-d469242517e1103\" rel=\"nofollow noopener\" target=\"_blank\">30<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 31\" title=\"Leccisotti L, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173. &#010;                  https:\/\/doi.org\/10.1186\/s12933-022-01607-4&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR31\" id=\"ref-link-section-d469242517e1106\" rel=\"nofollow noopener\" target=\"_blank\">31<\/a>]. The improvement in CFR was associated with a selective 19% reduction in EAT thickness and glucose uptake, suggesting a restoration of the protective effect of this fat depot. Indeed, the reestablishment of the protective function of EAT may have effects on microvascular dysfunction, potentially accounting for the observed improvements in CFR , as previously mentioned [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"Recio-Mayoral A, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009;30:1837\u201343. &#010;                  https:\/\/doi.org\/10.1093\/eurheartj\/ehp205&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR22\" id=\"ref-link-section-d469242517e1109\" rel=\"nofollow noopener\" target=\"_blank\">22<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 23\" title=\"Taqueti VR, Ridker PM. Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. JACC Cardiovasc Imaging. 2013;6:668\u201371. &#010;                  https:\/\/doi.org\/10.1016\/j.jcmg.2013.02.005&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR23\" id=\"ref-link-section-d469242517e1112\" rel=\"nofollow noopener\" target=\"_blank\">23<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 32\" title=\"Cinti F, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349. &#010;                  https:\/\/doi.org\/10.1186\/s12933-023-02091-0&#010;                  &#010;                .\" href=\"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02912-4#ref-CR32\" id=\"ref-link-section-d469242517e1115\" rel=\"nofollow noopener\" target=\"_blank\">32<\/a>].<\/p>\n<p>However, whether these benefits are maintained over longer periods remains unexplored. This follow-up study aimed to address this knowledge gap by evaluating the long-term effects of dapagliflozin on CFR, EAT and MEEi over a 4-year period, providing insights into its sustained cardioprotective potential.<\/p>\n","protected":false},"excerpt":{"rendered":"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with a significantly increased risk of cardiovascular&hellip;\n","protected":false},"author":2,"featured_media":109265,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[5239,64,63,5240,40134,78207,78209,1835,78211,78210,78208,105,7532],"class_list":{"0":"post-109264","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-technology","8":"tag-angiology","9":"tag-au","10":"tag-australia","11":"tag-cardiology","12":"tag-coronary-artery-disease","13":"tag-coronary-flow-reserve","14":"tag-dapagliflozin","15":"tag-diabetes","16":"tag-epicardial-adipose-tissue","17":"tag-long-term-coronary-flow-reserve","18":"tag-sglt2i","19":"tag-technology","20":"tag-type-2-diabetes"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/109264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=109264"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/109264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/109265"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=109264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=109264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=109264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}